Adjuvant Chemotherapy for Colorectal Cancer in the Era of Genomic Medicine
-
- Miyoshi Norikatsu
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University Department of Innovative Oncology Research and Regenerative Medicine, Osaka International Cancer Institute
-
- Fujino Shiki
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University Department of Innovative Oncology Research and Regenerative Medicine, Osaka International Cancer Institute
-
- Sekido Yuki
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Hata Tsuyoshi
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Hamabe Atsushi
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Ogino Takayuki
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Takahashi Hidekazu
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Uemura Mamoru
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Yamamoto Hirofuim
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Doki Yuichiro
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
-
- Eguchi Hidetoshi
- Department of Gastroenterological Surgery Graduate School of Medicine, Osaka University
Bibliographic Information
- Other Title
-
- IV.ゲノム医療時代の大腸癌術後補助化学療法
Abstract
<p>For postoperative stage III colorectal cancer, 6-month oxaliplatin combination therapy has been shown to reduce the risk of recurrence and death compared to 5-FU + l-LV, and is recommended as the most effective treatment option. Although non-inferiority of the 3-month treatment group to the 6-month treatment group was not shown, subgroup analysis showed superior disease-free survival in the 6-month treatment group in the FOLFOX group and non-inferiority of 3-month treatment in the CAPOX group. As for the side effects of neuropathy, it is important to consider the balance with the therapeutic effect because it is less in the 3-month administration group. In recent years, liquid biopsy has been used to evaluate the risk of recurrence by evaluating gene expression associated with cancer cells in tissue specimens by combining gene mutation analysis of BRAF, KRAS, and PIK3CA and the status of MSI. There is also widespread research to evaluate cell-free/circulating-tumor DNA. When selecting treatments, there is a problem of toxicity of long-term administration, so treatment should take into account the risk of recurrence, effects and balance.</p>
Journal
-
- Nippon Daicho Komonbyo Gakkai Zasshi
-
Nippon Daicho Komonbyo Gakkai Zasshi 75 (10), 468-472, 2022
The Japan Society of Coloproctology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390012423823446912
-
- ISSN
- 18829619
- 00471801
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
-
- Abstract License Flag
- Disallowed